Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5462 in renal impairment
NCT06661733Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD5462 (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time 0 to infinity, Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration and 8 more. Started Nov 2024; status: completed.
02
Drugs
AZD5462
Beyond the preview
Go deeper on NCT06661733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06661733.